Disease areas:
  • cancer and other tissue growths
Last updated:
Author(s):
Bhautesh Dinesh Jani, Michael K. Sullivan, Peter Hanlon, Barbara I. Nicholl, Jennifer S. Lees, Lamorna Brown, Sara MacDonald, Patrick B. Mark, Frances S. Mair, Frank M. Sullivan
Publish date:
25 October 2023
Journal:
British Journal of Cancer
PubMed ID:
37880510

Abstract

BackgroundIn the United Kingdom (UK), cancer screening invitations are based on general practice (GP) registrations. We hypothesize that GP electronic medical records (EMR) can be utilised to calculate a lung cancer risk score with good accuracy/clinical utility.MethodsThe development cohort was Secure Anonymised Information Linkage-SAIL (2.3 million GP EMR) and the validation cohort was UK Biobank-UKB (N = 211,597 with GP-EMR availability). Fast backward method was applied for variable selection and area under the curve (AUC) evaluated discrimination.ResultsAge 55-75 were included (SAIL: N = 574,196; UKB: N = 137,918). Six-year lung cancer incidence was 1.1% (6430) in SAIL and 0.48% (656) in UKB. The final model included 17/56 variables in SAIL for the EMR-derived score: age, sex, socioeconomic status, smoking status, family history, body mass index (BMI), BMI:smoking interaction, alcohol misuse, chronic obstructive pulmonary disease, coronary heart disease, dementia, hypertension, painful condition, stroke, peripheral vascular disease and history of previous cancer and previous pneumonia. The GP-EMR-derived score had AUC of 80.4% in SAIL and 74.4% in UKB and outperformed ever-smoked criteria (currently the first step in UK lung cancer screening pilots).DiscussionA GP-EMR-derived score may have a role in UK lung cancer screening by accurately targeting high-risk individuals without requiring patient contact.

Related projects

Our aim is to determine the extent and patterns of morbidity reporting and treatment use, and to investigate the impact of comorbidity, multimorbidity and polypharmacy…

Institution:
University of Glasgow, Great Britain

All projects